Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722602 | 0.83 | NOTUM (0.50) | TSHRALDH1A1NOTUMLMNATDP1 | |
| SCHEMBL5512574 | 0.83 | TDP1 (0.45) | TSHRALDH1A1LMNAEGFRCA2 | |
| SCHEMBL2499899 | 0.77 | TSHR (0.50) | TSHRALDH1A1LMNAEGFRCA2 | |
| SCHEMBL1041749 | 0.74 | NOTUM (0.43) | TSHRALDH1A1NOTUMLMNAHSD17B10 | |
| SCHEMBL4891656 | 0.74 | HSD17B1 (0.41) | TSHRALDH1A1LMNAEGFRCA2 | |
| SCHEMBL4120536 | 0.74 | ALDH1A1 (0.38) | ALDH1A1LMNAEGFRCA2FYN | |
| SCHEMBL936662 | 0.74 | NOTUM (0.43) | TSHRALDH1A1NOTUMLMNACYP1A2 | |
| SCHEMBL30368333 | 0.74 | ALDH1A1 (0.38) | ALDH1A1LMNAEGFRCA2FYN | |
| SCHEMBL22969778 | 0.74 | NOTUM (0.43) | TSHRALDH1A1NOTUMLMNATDP1 | |
| SCHEMBL29449840 | 0.74 | NOTUM (0.43) | TSHRALDH1A1NOTUMLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655456-A | Method for efficiently purifying and separating 2-chloro-4-trifluoromethyl phenol | 上虞颖泰精细化工有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-117510497-A | DGK zeta inhibitors | 山东轩竹医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116655456-A | Method for efficiently purifying and separating 2-chloro-4-trifluoromethyl phenol | 上虞颖泰精细化工有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022020305-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-27 | — | — | WO | disclosed |
| US-5382686-A | Process for preparing nitrodiphenyl (thio) ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-17 | — | — | US | disclosed |
| EP-0304725-B1 | PROCESS FOR THE PREPARATION OF NITRO-DIPHENYL(THIO) ETHERS | BAYER AG (DE) | 1992-01-22 | — | — | EP | disclosed |
| EP-0298803-B1 | PROCESS FOR THE PERHALOALKYLATION OF AROMATIC DERIVATIVES | RHONE-POULENC CHIMIE (FR) | 1991-09-04 | — | — | EP | disclosed |
| EP-0206951-B1 | PROCESS FOR THE PERFLUOROALKYLATION OF AROMATIC DERIVATIVES | RHONE-POULENC CHIMIE (FR) | 1990-03-21 | — | — | EP | disclosed |
| EP-0304725-A1 | Process for the preparation of nitro-diphenyl(thio) ethers | BAYER AG (DE) | 1989-03-01 | — | — | EP | disclosed |
| EP-0298803-A1 | Process for the perhaloalkylation of aromatic derivatives | RHONE-POULENC CHIMIE (FR) | 1989-01-11 | — | — | EP | disclosed |
| US-4731450-A | Process for perfluoroalkylation of aromatic derivatives | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-03-15 | — | — | US | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0206951-A2 | Process for the perfluoroalkylation of aromatic derivatives | RHONE-POULENC CHIMIE (FR) | 1986-12-30 | — | — | EP | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| US-4504689-A | Process for the preparation of phenates substituted by halogen groups or of the corresponding phenols | RHONE-POULENC AGROCHIMIE (FR) | 1985-03-12 | — | — | US | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | TSHR 19/4885ALDH1A1 2655/4885NOTUM 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.